Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Dec 9, 2017 in Prostate cancer | 0 comments

In a nutshell

This study aimed to evaluate active surveillance as an option in intermediate stage prostate cancer. It found that it should be based on multiple criteria, but is still a viable option. Gleason score, PSA, volume of cancer in biopsy, age, and MRI results should all play a role in making the decision. 

Some background

Active surveillance is an option in early stage prostate cancer instead of active treatment. This involves monitoring the prostate for any changes by regular testing. Its use in intermediate risk prostate cancer is unclear.

Methods & findings

This study reviewed trials to determine the effectiveness of active surveillance for intermediate risk prostate cancer.

The best candidates for surveillance are those with low PSA (prostate specific antigen, a protein present in prostate cancer) or Gleason pattern 4 (Gleason pattern is an indication of how aggressive the cancer is). The size of the tumor, the age of the patient, and other illnesses at the time of diagnosis should also be taken into consideration. 

The bottom line

This study found that the decision to undergo active surveillance in intermediate stage prostate cancer should be based on multiple criteria, but is still a viable option.

The fine print

Some trials mentioned in this study were carried out before MRI was common and this could impact findings. 

Published By :

Current urology reports

Date :

Aug 11, 2017

Original Title :

Active Surveillance for Intermediate Risk Prostate Cancer.

click here to get personalized updates